Advertisement
Notícias Forex
Dollar Stays Firm Against Major Rivals
The U.S. dollar firmed against several major currencies on Thursday amid falling risk appetite due to rising possibility of a recession.
RTTNews |
1133 dias atrás
Swiss Market Ends On Weak Note
The Switzerland stock market ended on a negative note on Thursday after staying weak right through the day's session amid persisting worries about inflation and slowing global growth.
RTTNews
|
1133 dias atrás
Norway Central Bank Hikes Policy Rate By 50 Bps
The Norwegian central bank joined several of its peers in delivering a bigger than expected 50 basis point hike on Thursday amid the woes of high inflationary pressures and policymakers hinted that there will be another rate hike in August.
RTTNews
|
1133 dias atrás
European Stocks Close Lower Again On Recession Fears
After recovering from a weak start and even managing a brief spell in positive territory around early afternoon, European stocks fell and ended notably lower on Thursday, weighed down by fears about the possibility of a recession.
RTTNews
|
1133 dias atrás
UK Private Sector Logs Steady Growth In June
The UK private sector logged a better-than-expected growth in June but that was unchanged from the 15-month low seen in May, flash survey results from S&P Global showed on Thursday. The Chartered Institute of Procurement & Supply flash composite output index held steady at 53.1 in June, while the reading was expected to fall to 52.6. The score remained above the neutral 50.0.
RTTNews
|
1133 dias atrás
U.S. Weekly Jobless Claims Edge Slightly Lower To 229,000
First-time claims for U.S. unemployment benefits edged slightly lower in the week ended June 18th, according to a report released by the Labor Department on Thursday. The report showed initial jobless claims dipped to 229,000, a decrease of 2,000 from the previous week's revised level of 231,000.
RTTNews
|
1134 dias atrás
CNS Pharma Says FDA Oks Protocol Amendment To PPivotal Global Trial Of Berubicin For GBM
Biopharmaceutical company CNS Pharmaceuticals, Inc. (CNSP) announced Thursday that it has received approval from the U.S. Food and Drug Administration (FDA) for its ongoing potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine (Gleostine) administered after first line therapy for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.
RTTNews
|
1134 dias atrás
more news
U.S. Weekly Jobless Claims Edge Slightly Lower
First-time claims for U.S. unemployment benefits edged slightly lower in the week ended June 18th, according to a report released by the Labor Department on Thursday.
RTTNews
|
1134 dias atrás
Bay Street May Open Slightly Higher
Slightly higher U.S. and Canadian futures point to a positive start for the Canadian market Thursday morning. However, sluggish commodity prices and concerns about inflation and rate hikes are likely to render the mood cautious.
RTTNews
|
1134 dias atrás
Xperi Holding Boosts FY22 Revenues Outlook
Xperi Holding Corp. (XPER) announced Thursday a $10 million increase in both its annual revenue and operating cash flow guidance for 2022, primarily due to a recently resolved contract dispute with a customer.
RTTNews
|
1134 dias atrás
Euro Drops As Eurozone Business Activity Slows Sharply
The euro declined against its major counterparts in the European session on Thursday, as Eurozone business growth slowed sharply to a 16-month low in June as demand stalled and price pressures remained elevated.
RTTNews
|
1134 dias atrás
Amryt Pharma Says European Commission Oks Filsuvez For Dystrophic And Junctional EB
Biopharmaceutical company Amryt Pharma plc (AMYT) announced the European Commission (EC) approval of Filsuvez in the European Union (EU) for the treatment of partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older.
RTTNews
|
1134 dias atrás
Rite Aid Boosts FY22 Revenues Outlook As Q1 Results Come Above Estimates
While reporting financial results for the first quarter of fiscal 2022 on Thursday, drugstore chain Rite Aid Corp. (RAD) raised it total revenue guidance for the full-year 2022, due to increased utilization of higher cost drugs at Elixir.
RTTNews
|
1134 dias atrás
Stay up to date!
Add Notícias to your browser
Add To Chrome
